InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,576.98
(
0.07%
)
US TECH 100
19,926.40
(
0.16%
)
Dow Jones
39,291.97
(
-0.13%
)
Brent Oil
84.11
(
-0.70%
)
Bitcoin
58,391.22
(
0.64%
)
Post# of 252545
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120010
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 221623

Thursday, 03/07/2019 5:22:51 PM

Thursday, March 07, 2019 5:22:51 PM

Post# of 252545
SNDX -12%/AH on Entinostat failures in ovarian and TNBC:

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-fourth-quarter-2018-financial-results-and-provides-clinical-and-business-update-300808834.html

The Phase 1b/2 ENCORE 603 trial, which evaluated entinostat in combination with avelumab in patients with heavily pretreated advanced epithelial ovarian cancer, and the Phase 1b/2 ENCORE 602 trial, which evaluated entinostat in combination with atezolizumab in patients with PD-1 naïve, previously treated TNBC, each failed to meet its respective primary endpoint of a statistically significant improvement in PFS.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up